Cargando…
Analysis of infections among patients with historical culture positive for extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli or Klebsiella pneumoniae: Is ESBL-targeted therapy always needed?
OBJECTIVE: Among patients with a history of ESBL infection, uncertainty remains regarding whether all of these patients require ESBL-targeted therapy when presenting with a subsequent infection. We sought to determine the risks associated with a subsequent ESBL infection to help inform empiric antib...
Autores principales: | Stone, Tyler J., DeWitt, Michael, Johnson, James W., Beardsley, James R., Munawar, Iqra, Palavecino, Elizabeth, Luther, Vera P., Ohl, Christopher A., Williamson, John C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031583/ https://www.ncbi.nlm.nih.gov/pubmed/36970424 http://dx.doi.org/10.1017/ash.2022.363 |
Ejemplares similares
-
838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
por: Stone, Tyler J, et al.
Publicado: (2020) -
182. Piperacillin/tazobactam (P/T) versus meropenem (Mero) for treatment of extended-spectrum beta-lactamase (ESBL)-producing E.coli and K. pneumoniae bloodstream infections (BSIs)
por: Cox, Alexandra L, et al.
Publicado: (2023) -
Extended-Spectrum β-Lactamases (ESBL): Challenges and Opportunities
por: Husna, Asmaul, et al.
Publicado: (2023) -
Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence
por: Marra, Alexandre R, et al.
Publicado: (2006) -
Moxalactam is not more active on extended spectrum β-lactamase (ESBL) producing bacteria than on non-ESBL producers
por: Singh, Bhoj R
Publicado: (2018)